Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients

Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogeneic Hematopoietic Cell Transplant Recipients: AdVance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04285788

Acronym

AdVance

Enrollment

216

Registered

2020-02-26

Start date

2013-01-31

Completion date

2017-01-31

Last updated

2022-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenovirus Infections, Human

Brief summary

To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients. It is expected that participating centers will be in the United Kingdom, France, Spain, Germany, and Italy.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

0 Months to 90 Years

Healthy volunteers

Inclusion criteria

* At least one AdV positive test, regardless of specimen within 6 months following the first allo-HCT * Subjects first allo-HCT must have been performed between 1 January 2013 and 30 September 2015

Exclusion criteria

* AdV negative

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with non-relapse related mortality 3 and 6 months after first AdV Virema in paediatric allo-HCT recipients	3 and 6 months after first adenovirus viremia	To assess non-relapse related mortality 3 to 6 months after first adenovirus viremia.

Secondary

Measure	Time frame	Description
Number of participants who were hospitalized To assess the number of hospitalizations	3 to 6 months	To assess the number of hospitalizations, length of stay, and ICU stay.
The rate of adenovirus infection progression	3 to 6 months	To assess the rate of progression to disseminated adenovirus disease within the first year following allo-HCT

Outcome results